Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from July 2022.

Interesting empirical studies, policy analyses, and editorials on health law and policy issues from July 2022.

Medical students spend a lot of time learning about conditions they will likely never treat. This has negative implications for patient care.

Should performance-enhancing drugs that improve innovation and creativity be treated like those that enhance athleticism?

Interesting empirical studies, policy analyses, and editorials on health law and policy issues from March 2022.

Microdosing is certainly possible under the Oregon Psilocybin Services Act.

Massive and misleading promises are an unfortunate reality for many fitness products. But regulators can promote accountability.

The future of work and of aging will be shaped by struggles over care from both giving and receiving ends, perhaps against those profiting in between.
